<SEC-DOCUMENT>0001193125-21-195039.txt : 20210621
<SEC-HEADER>0001193125-21-195039.hdr.sgml : 20210621
<ACCEPTANCE-DATETIME>20210621160618
ACCESSION NUMBER:		0001193125-21-195039
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210616
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210621
DATE AS OF CHANGE:		20210621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		211030535

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d183984d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oric="http://www.oricpharma.com/20210616" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityAddressAddressLine2" name="dei:EntityAddressAddressLine2" contextRef="duration_2021-06-16_to_2021-06-16">2nd Floor</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-06-16_to_2021-06-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-06-16_to_2021-06-16">0001796280</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="oric-20210616.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-06-16_to_2021-06-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-16</xbrli:startDate> <xbrli:endDate>2021-06-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-06-16_to_2021-06-16">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt:datemonthdayyearen">June 16, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-06-16_to_2021-06-16">ORIC Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-06-16_to_2021-06-16">001-39269</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-06-16_to_2021-06-16">47-1787157</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-06-16_to_2021-06-16">240 E. Grand Ave</ix:nonNumeric>, 2<sup style="font-size:85%; vertical-align:top">nd</sup> <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressAddressLine2">Floor</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-06-16_to_2021-06-16">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-06-16_to_2021-06-16">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-06-16_to_2021-06-16">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-06-16_to_2021-06-16">(650)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-06-16_to_2021-06-16">388-5600</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-06-16_to_2021-06-16">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-06-16_to_2021-06-16">ORIC</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:exchnameen">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2021-06-16_to_2021-06-16" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;5.07 Submission of Matters to a Vote of Security Holders. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;16, 2021, ORIC Pharmaceuticals, Inc. (the &#8220;Company&#8221;) held its annual meeting of stockholders. Of the 36,695,814 shares of common stock outstanding as of April&#160;19, 2021, the record date for the meeting, 31,175,574 shares of common stock were represented at the meeting in person or by proxy, constituting 84.96% of the outstanding common stock entitled to vote. The matters voted upon at the meeting and the vote with respect to each such matter are set forth below: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal 1 - Election of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Election of two Class&#160;I directors to hold office until the 2024 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class&#160;I director, to hold office until the Company&#8217;s 2024 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Nominees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Withheld</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Heyman, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,152,443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,472,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,550,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lori Kunkel, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,079,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,545,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,550,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointment of KPMG LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2021 was ratified based on the following results of voting: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:25%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">31,174,833</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">739</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#8212;&#160;&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2021, the Company issued a press release announcing initial data from its Phase 1b clinical trial of <span style="white-space:nowrap">ORIC-101</span> in combination with <span style="white-space:nowrap">nab-paclitaxel.</span> A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d183984dex991.htm">Press release dated June&#160;2, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">ORIC PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: June&#160;21, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic Piscitelli</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-3- </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d183984dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g183984g01p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of <FONT
STYLE="white-space:nowrap">ORIC-101</FONT> in Combination with <FONT STYLE="white-space:nowrap">Nab-Paclitaxel</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;2, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events
primarily Grade 1 or 2, with no treatment-related discontinuations </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">ORIC-101</FONT> plasma
concentrations provided excellent target coverage; no evidence of drug-drug interaction with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Translational data showed pharmacodynamic modulation of GR biomarkers and high rates of GR expression in tumor types of interest </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Antitumor activity demonstrated across multiple advanced solid tumors in heavily pretreated patients, including those previously treated
with a taxane-based therapy </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Extended PFS observed in patients with late-line relapsed pancreatic cancer who had previously
progressed on or after <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference call and webcast today at 5:00 p.m. ET
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) &#151; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology
company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data from an ongoing Phase 1b study evaluating <FONT STYLE="white-space:nowrap">ORIC-101,</FONT> a glucocorticoid receptor
antagonist, in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> in advanced solid tumors. The data will also be presented in two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held
June&nbsp;4 &#150; 8, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to share initial data from our <FONT STYLE="white-space:nowrap">ORIC-101</FONT> clinical program in
patients with advanced solid tumors. We are pleased that the combination was well tolerated without evidence of drug-drug interaction and has demonstrated both tumor regression and prolonged stable disease in multiple heavily pretreated
tumors,&#148; said Pratik S. Multani, MD, chief medical officer. &#147;Although early, we are particularly intrigued by the potential benefit seen in patients with late-line relapsed pancreatic cancer previously treated with <FONT
STYLE="white-space:nowrap">nab-paclitaxel,</FONT> as any retreatment benefit in such patients would not be expected. We are continuing to enroll patients in the expansion cohorts and look forward to reporting updated data from the Phase 1b trial in
2022.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Having been involved with this study from its design stage, I feel we have developed an optimal combination for this heavily pretreated
patient population,&#148; said Professor Pamela Munster, MD, Director of the University of California San Francisco&#146;s Early Phase Clinical Trials Unit, and trial investigator and senior author of the ASCO poster. &#147;I&#146;m impressed by the
extended time on treatment we&#146;ve seen in patients with late-line pancreatic cancer; seeing clinical activity in these patients is quite remarkable.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Trial Design and Initial Results from Phase 1b Clinical Trial </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">ORIC-101</FONT> in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> is a
single arm, multicenter, open-label study conducted in two parts, intended to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity when administered to patients with advanced
or metastatic solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Part I dose escalation portion of the study, five cohorts of patients across multiple solid tumors were enrolled to
evaluate <FONT STYLE="white-space:nowrap">ORIC-101</FONT> doses ranging from 80 to 240 mg administered orally in both intermittent and continuous once daily dosing regimens, in combination with either 75 or 100 mg/m<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP> <FONT STYLE="white-space:nowrap">nab-paclitaxel.</FONT> Following the completion of the dose escalation portion of the study, the RP2D was determined to be 160 mg of
<FONT STYLE="white-space:nowrap">ORIC-101</FONT> continuous once daily dosing and 75 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> of <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> on days 1, 8, and 15 of a <FONT
STYLE="white-space:nowrap">28-day</FONT> cycle, without requirement for prophylactic granulocyte-colony stimulating factor <FONT STYLE="white-space:nowrap">(G-CSF).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Part II dose expansion portion of the study, up to 132 patients are expected to be enrolled across four cohorts, including pancreatic ductal
adenocarcinoma (PDAC), ovarian cancer, triple negative breast cancer, and other advanced solid tumors. Enrollment continues in the Part II dose expansion cohorts at 12 clinical sites across the United States. Patients in the dose expansion portion
of the study are required to have previously progressed on a taxane-based therapy, with retrospective analysis of GR expression and other potentially predictive biomarkers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Safety Analyses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of March&nbsp;31, 2021, a total of 31 patients were enrolled across Parts I/II of the study, which included 12
patients treated at <FONT STYLE="white-space:nowrap">non-RP2D</FONT> doses and 19 patients treated at the RP2D of 160 mg of <FONT STYLE="white-space:nowrap">ORIC-101</FONT> continuous once daily dosing and 75 mg/m<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP> of <FONT STYLE="white-space:nowrap">nab-paclitaxel.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients treated at the RP2D were heavily pretreated, with a median of four prior therapies, and all had
previously received a taxane-based therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of the database cutoff date of April&nbsp;21, 2021, the RP2D was well tolerated; treatment-related adverse
events were primarily Grade 1 or 2, with only three Grade 3 events, which all resolved with dose interruption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no treatment-related discontinuations and no requirement for prophylactic <FONT
STYLE="white-space:nowrap">G-CSF</FONT> at the RP2D. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary Antitumor Activity (as of the database cutoff date of April&nbsp;21,
2021): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The efficacy evaluable population included a total of 23 patients who had an opportunity for at least one <FONT
STYLE="white-space:nowrap">on-treatment</FONT> tumor assessment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Five partial responses were observed, one confirmed and four unconfirmed, including in heavily pretreated
patients with PDAC, endometrial and breast cancers, who previously progressed on or after a taxane-based therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further evidence of antitumor activity was demonstrated by prolonged disease stabilization across multiple solid
tumors, including PDAC, breast, gastric, esophageal, and testicular cancers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Notably, three of the four efficacy evaluable patients with late-line relapsed PDAC treated at the RP2D
demonstrated extended progression free survival ranging from 3.6 months to 5.3+ months in the third-line or later setting, despite having already previously progressed on <FONT STYLE="white-space:nowrap">nab-paclitaxel.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster presentations will be on the ORIC website on June&nbsp;4, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ORIC-101</FONT> is also being evaluated in a Phase 1b trial in combination with Xtandi (enzalutamide) in metastatic prostate
cancer, which is also currently enrolling to the dose expansion portion of the study, and initial interim safety, efficacy, and translational data are expected in the second half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast and Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC will host a conference
call and webcast, today at 5:00 p.m. ET. To participate in the conference call, please dial (833) <FONT STYLE="white-space:nowrap">651-0991</FONT> (domestic) or (918) <FONT STYLE="white-space:nowrap">922-6080</FONT> (international) and refer to
conference ID 4783288. A live webcast and audio archive of the conference call will be available through the investor section of the company&#146;s website at <U>www.oricpharma.com</U>. The webcast will be available for replay for 90 days following
the presentation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">ORIC-101</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ORIC-101</FONT> is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to
resistance to multiple classes of cancer therapeutics across a variety of solid tumors. Preclinical in vitro and in vivo data suggest <FONT STYLE="white-space:nowrap">ORIC-101</FONT> is able to address key resistance mechanisms of multiple classes
of cancer treatments, including taxanes and androgen receptor modulators. Based on preclinical and clinical studies, <FONT STYLE="white-space:nowrap">ORIC-101</FONT> is expected to have reduced drug-drug interaction liabilities than other
glucocorticoid receptor antagonists. Currently, there are no glucocorticoid receptor antagonists approved by the FDA for the treatment of cancer. Following the successful completion of two Phase 1a trials in over 50 healthy volunteers, ORIC
initiated two separate Phase 1b trials of <FONT STYLE="white-space:nowrap">ORIC-101</FONT> in combination with (1)&nbsp;Abraxane <FONT STYLE="white-space:nowrap">(nab-paclitaxel)</FONT> in advanced or metastatic solid tumors and (2)&nbsp;Xtandi
(enzalutamide) in metastatic prostate cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ORIC Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients&#146; lives by <I><U>O</U>vercoming <U>R</U>esistance
<U>I</U>n</I> <I><U>C</U>ancer. </I>ORIC&#146;s lead product candidate, <FONT STYLE="white-space:nowrap">ORIC-101,</FONT> is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to
multiple classes of cancer therapeutics across a variety of solid tumors. <FONT STYLE="white-space:nowrap">ORIC-101</FONT> is currently in two separate Phase 1b trials in combination with (1)&nbsp;Abraxane
<FONT STYLE="white-space:nowrap">(nab-paclitaxel)</FONT> in advanced or metastatic solid tumors and (2)&nbsp;Xtandi (enzalutamide) in metastatic prostate cancer. ORIC&#146;s other product candidates include
<FONT STYLE="white-space:nowrap">(1)&nbsp;ORIC-533,</FONT> an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment
regimens, <FONT STYLE="white-space:nowrap">(2)&nbsp;ORIC-944,</FONT> an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and
<FONT STYLE="white-space:nowrap">(3)&nbsp;ORIC-114,</FONT> a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers.
Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to
<U>www.oricpharma.com</U>, and follow us on <U>Twitter</U> or <U>LinkedIn</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements as that term is defined in Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of <FONT
STYLE="white-space:nowrap">ORIC-101</FONT> in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel;</FONT> clinical outcomes, which may materially change as patient enrollment continues or more patient data become available; the expected
timing of reporting updated data from the <FONT STYLE="white-space:nowrap">ORIC-101</FONT> clinical trial in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel;</FONT> the expected timing of reporting the initial data from the <FONT
STYLE="white-space:nowrap">ORIC-101</FONT> clinical trial in combination with enzalutamide; the potential benefits of <FONT STYLE="white-space:nowrap">ORIC-101</FONT> or the company&#146;s other product candidates; and statements by the
company&#146;s chief medical officer and Dr.&nbsp;Munster. Words such as &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;goal,&#148; &#147;potential&#148; and
similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC&#146;s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC&#146;s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and
commercialize any of its product candidates; changes in ORIC&#146;s plans to develop and commercialize its product candidates; the potential for clinical trials of <FONT STYLE="white-space:nowrap">ORIC-101,</FONT>
<FONT STYLE="white-space:nowrap">ORIC-533,</FONT> <FONT STYLE="white-space:nowrap">ORIC-944,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT> or any other product candidates to differ from preclinical, initial, interim, preliminary or
expected results; negative impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on ORIC&#146;s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to
the termination of ORIC&#146;s license agreements; ORIC&#146;s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries;
ORIC&#146;s reliance on third parties, including contract manufacturers and contract research organizations; ORIC&#146;s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or
management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled &#147;Risk Factors&#148;
in ORIC&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on May&nbsp;6, 2021, and ORIC&#146;s future reports to be filed with the SEC. These
forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking
statements, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains interim results based on initial data from the
<FONT STYLE="white-space:nowrap">ORIC-101</FONT> clinical trial in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> including preliminary safety and antitumor activity analyses, as of the data cutoff date. These initial data,
results and related findings and conclusions are subject to change materially based on patient data subsequent to the cutoff date or as patient enrollment continues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli, Chief Financial
Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>dominic.piscitelli@oricpharma.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>info@oricpharma.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>oric-20210616.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 6/21/2021 10:19:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:oric="http://www.oricpharma.com/20210616"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.oricpharma.com/20210616"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20210616_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20210616_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>oric-20210616_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 6/21/2021 10:19:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>oric-20210616_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 6/21/2021 10:19:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="oric-20210616.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g183984g01p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g183984g01p01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H CFFAMHI)YY8X(($:26:9UBBAC0%GDDD<A8T5026)
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MNI@I4:G_ #\I5JL9?=*4X.W2\6>P^&OCKI]V\=MXEL#ICL0HO[+?/9@G S-
MV9H5SGE3-COBOZ(X+^E+D^/J4L%QGE;R2K-J*QV$<Z^#OHKU:,KXBA'S@\0E
MULM3\]SGPOQF&C*MDV*6-A'7V%6U.M9=(S5J<WY-4_*Y[M9WEK?VT-Y8W$5U
M:SH'AG@=9(I$/0JRG'L1U!&#R*_J;+\PP.:8.AF&68NECL#BHJ=&O0G&I2G%
M]8SBVG;9K=---)IH_+Z^'KX2M4P^)I3H5J3Y9PG%QE%KHT[/_/=%FNPQ"@#X
MN_;6^+OC[X/^"O"FK_#_ %F/1=0U/Q%/87L\FFZ;J8EM4L6F6,1:G:7"1D2
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M_P"%2_"O_HF?P^_\(SPY_P#*VCZYC/\ H+K?^#9__)!_8&1?]"7 ?^$>'_\
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M_$_]H7X@2068U7Q?XMUJ9;C4M2O))KA+.V+I";O4+M@RV.FP!D09VHBA41>
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M /W'4_C7['"49Q4HNZ>WRT/X7K49X>K*C57+.G:Z^2:_!G]*OP7OK?4O@_\
M"R^M2I@N?AWX,D0+T0CP[IRO$1V:.17C([%".U?D^/BX8[&0>CC7J_\ I<OS
M/[.X;JPK</9%5I_!/ 8-JW3_ &>FFO6+NGV:/3*Y#V@H * "@ H CE<1122-
M]V.-W;/'"*6//;@4)7LN^@F^1-[<JO\ <?E'=_\ !0KPU'JES:0_ /2+M$OY
MK:*\_P"$KLE-TBW#1)<^7_P@[E3(H#[=[8W8W'J?=_XAQD\E[2>&P2G)<TKY
M?0;YGJ[MN[=]WU/QV7CUF%.K*A2R[%2A";A!K-:J3BGRQ:BL.[)I)I)Z;7/U
M7LI'EL[262W%I));02/:AMPMG>)&:W#;$W"-B4SM7.WH.@\+EC#W(64(Z1LK
M*RT5DME;HMC]AA.4X0G-.,Y)2DF[M2:NTWI=IZ7LKGR3^V)\;/&OP/\ !_A?
M6_!!TE;W5M?GTZ[_ +7L'OX?LT=DTZ^5&ES#LD\P#YLGCC%>YD67X?'UZU+$
M<W+""DN5V=[V[,_/_$/B7,N&,NP.)RSV2J5Z\J<O:P<URJ',K)2C9WZGYX?\
M/!?V@?[W@K_PG)__ ):U]1_JQEG_ $]_\#7_ ,B?D7_$6^+/^H+_ ,)Y?_+0
M_P"'@O[0/][P5_X3D_\ \M:/]6,L_P"GO_@:_P#D0_XBWQ9_U!?^$\O_ ):'
M_#P7]H'^]X*_\)R?_P"6M'^K&6?]/?\ P-?_ "(?\1;XL_Z@O_">7_RTYK6O
MVSOVE/&JKHUAXF_LV2\81I;^$="M;349V(($<%PL5Q=HW/\ RPD1NG/%:T\A
MRG#>_*ES*/6I-N*]5I'[T<6)\1^,\Q2PU'&>P=311PE",:C\HRM.HG_A:9>^
M&W['WQS^+^KC6O%=GJ?A72[V?S]2\2>-3=)JUWN8M));:=>-]OO9GYVR2+'$
M21F45.*SS+L##V="4:TXJT:=*W*K::R7NQMY7?D;9-X=\4<08A8G,*=3 4*C
M4JF(QG-[::>K<:<W[6<GT<E&/]X_9/X1?"'PC\%_"5MX4\)VI5%VSZIJDZJ=
M0UF_V[7O+V11]1'$#LC7Y5Y+,WPF.QU?'5W6K/RC%?#"/1)?F^I_17#_  _E
M_#>7PP& I\J6M2I*WM*T[:SFU_Y+%:16BZM^I5QGN'R[^V9_R;A\1O\ KUTG
M_P!/FFU[&0_\C7"^LO\ TB1\/XC?\D;G'^"E_P"GZ9^<W_!.W_DN>J?]B#K?
M_IST.OJ>*/\ D70_Z_0_])F?CWA!_P E/7_[ :W_ *<HG[=U^?'],GQE^WM:
MRW'[.>O2Q*2EAXB\*W4Y /R0OJT=BI..@\^\A'_ A7O<-M1S2DOYH5$O_ ;_
M ))GYQXJTY2X.Q<HK2EB,+*7DO:J'_I4XH_-?]AK4+>P_:/\&I<.D?V^P\2Z
M? TC!0;B30KVXB12Q WO]F9%'4E@!R17U?$47+*J]OL2IM^G.E^%S\9\+ZL*
M/&.7*;4?:T\13C?^9T)R2]7RV7W'[ZU^;']6A0 4 % !0 4 % 'X,_MQ_#3_
M (0#XTW6HV-H;;P_XSTNPUC2MH @BN;&V@TK5+*(@#!BEM8)B#R%ODY.<U^C
M\.XOZS@%"4N:KAY.,N]FW*+_ !:_[=/Y7\3\E_LGB2=:E3Y,)F-*%6E;X5*G
M&-*I!?X7&,K=IH^ZOV /BS:>*OA>_P -[^[0>(OA_<3I9P2R#S[SPQJ=S->V
M-Q$&P9!9WDUW9N%SY<:6>3^\%?.\2X)T,8L5%?NL2E=]%4BK->7,DI>;YNQ^
MH^$V?0QV1O)ZLU];R>348MZRPU23E"2[^SG*5-V^&*IW^)'WY7S1^KA0 4 %
M !0!\R_M:?%BU^%/P<\17$<\:^(/$UK<>&?#EON'FF[U*"2&YO5C$BMY=G9M
M-,6&0'$2D'> ?6R3!/&8ZE&W[J@U4F^EHNZ7_;SLK=K]CXKC[/J>0\.XR:FH
MXO&QEAL/'KSU(N,IVNG:G"\K[7Y4]S\7OV;/A[<?$KXS^!O#J0O)81:Q;:QK
M;",O'%HVC.-0O_-8<1>;% 8$9N/,GC&"6 /WV;8E8/ 8BK>TN5QA_BE[J];7
MOZ)G\W\%Y1/.N),LP:CS4HU8UJSMHJ-%^TG=].91Y4_YI+<_H[K\K/[%/SB_
MX*1_\DW\"?\ 8VW7_IL>OJ>%/][Q'_7M?^E'X[XR_P#(FRO_ +"I?^FV>3_\
M$^_ASX!\<Z/\1)O&7@SPSXJET_4M&BL9/$&BV&K-:1S6MP\J6YO8)/*5F12=
MN.E=W$V*Q.&J858>O4H*4974).-[-6O9J]CP?"7)\JS/#9Q+,<MPV.E1J45!
MUZ-.KR)QDVH\\96O97L?HO\ \,_? S_HD'PW_P#"-T#_ .0:^6_M/,?^@ZO_
M .#9_P"9^P?ZI\+_ /1/9=_X1T/_ ) P?$_[,7P,\2^'M7T$?#3P;H;ZI8S6
ML6L:#X<TG3-8TR=AF"^T^]M;5)(IX9EC<+NV2!3'(K1NZMI1S?,:-6G4^MU9
MJ#3Y9SDXR75--M6:T\MUJCDQO!/"^-PF(PO]BX/"NO!Q56AAZ5*K2E]F=.<8
MIJ479VO:5N62<6T_PT\8>%O'O[-GQ8-B9[C3/$7A74TU#0M9@5XK?4[ 2,;/
M4;8AOWME=6^4DCW'&^6&3#JP'Z'0K8;-<%>RE2K1Y9PZQ?6+[.+V?HT?S#F&
M!S7@O/\ V7.Z&+P%15*%:*:C5A?W*D>\)QTE'I>4):IG[L? #XUZ+\<O -CX
MHL!%::O;;+#Q+HZR!GTS5HXD:4(I.\V4V?,A=@,J2IR4-?G698"IEV)E1E=P
M>M.7\T>GS6S7<_J/A3B3#<3952QU&U.O"T,113UI54M5WY)?%!O=:;IGM]>>
M?3!0!\N_MF?\FX?$;_KUTG_T^:;7L9#_ ,C7"^LO_2)'P_B-_P D;G'^"E_Z
M?IGYS?\ !.W_ )+GJG_8@ZW_ .G/0Z^IXH_Y%T/^OT/_ $F9^/>$'_)3U_\
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ML;>5@H _.+_@I'_R3?P)_P!C;=?^FQZ^IX4_WO$?]>U_Z4?COC+_ ,B;*_\
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14HQ2BHZ)+1)+9)+:PZ@9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d183984d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="oric-20210616.xsd" xlink:type="simple"/>
    <context id="duration_2021-06-16_to_2021-06-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <dei:EntityAddressAddressLine2
      contextRef="duration_2021-06-16_to_2021-06-16"
      id="Hidden_dei_EntityAddressAddressLine2">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:AmendmentFlag contextRef="duration_2021-06-16_to_2021-06-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-06-16_to_2021-06-16"
      id="Hidden_dei_EntityCentralIndexKey">0001796280</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-06-16_to_2021-06-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-06-16_to_2021-06-16">2021-06-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-06-16_to_2021-06-16">ORIC Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-06-16_to_2021-06-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-06-16_to_2021-06-16">001-39269</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-06-16_to_2021-06-16">47-1787157</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-06-16_to_2021-06-16">240 E. Grand Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-06-16_to_2021-06-16">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-06-16_to_2021-06-16">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-06-16_to_2021-06-16">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-06-16_to_2021-06-16">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-06-16_to_2021-06-16">388-5600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-06-16_to_2021-06-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-06-16_to_2021-06-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-06-16_to_2021-06-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-06-16_to_2021-06-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-06-16_to_2021-06-16">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-06-16_to_2021-06-16">ORIC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-06-16_to_2021-06-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-06-16_to_2021-06-16">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2021-06-16_to_2021-06-16">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140143711076232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 16, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001796280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 16,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORIC Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1787157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">240 E. Grand Ave<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-5600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORIC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MQ8#54@J%Z,)S!   B1$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF%USXC84AJ^WOT+#]**=2;"M\+D#S!"2;-/=36B@W9EV>B%L 9K8DE>2 _S[
M'AFPV:TYIKT!&ZR71^=([SEBL%'ZU:PYMV2;Q-(,&VMKT_>>9\(U3YAIJI1+
M^&:I=,(LW.J59U+-690/2F*/^G['2YB0C=$@_VRJ1P.5V5A(/M7$9$G"].Z6
MQVHS; 2-XP<O8K6V[@-O-$C9BL^X_3V=:KCS"I5()%P:H231?#ELC(/WM[3C
M!N1/_"'XQIQ<$S>5A5*O[N8Q&C9\1\1C'EHGP>#MC4]X'#LEX/AZ$&T4O^D&
MGEX?U1_RR<-D%LSPB8J_B,BNAXU>@T1\R;+8OJC-+_PPH;;3"U5L\E>RV3_;
M\ALDS(Q5R6$P$"1"[M_9]A"(TP'TS !Z&$!S[OT/Y91WS++10*L-T>YI4',7
M^53ST0 GI,O*S&KX5L X.[I3809!MH3)B-Q+*^R./,I]MB%J \_"C[A'O? @
M>+L7I&<$?\UDDP2=*T)]&GP[W .V I 6@#37NSFC-U%O7)._Q@MC-:3P;T3R
MII"\R25;9R0/TQQ'D>;&7!TOR"=XCLPWJFK2N"*%X#W$2FF$KE70M5"M,:0C
MRE/R$+-5%0L^?LEBPQ&.=L'1OB1*$R#1+(9%$?$M^<AW542XDN_[0;??H3T?
MP>H46!U4K%BP\UW*JUCPX;WKCPA$MX#H7@8QY5HHMW$B MNOD@=7.FZ7']Z]
MJ]DPO8*M=TG>7OA*N"T#D$\LJ23#=9Y?'B=DNF;@!"'/K AA75W!,@B;"&2_
M@.Q? @EJ2J=*YUY#9A9"2"8J@Q4'"T]%E=2X\-T]0A?XI2OZE_ ]B)B3IRQ9
M<%WIA+@(+/OKFS[M]#&D$Z,.+D&:LRUYC&#MB26D)(\; HA+MKK70;?7#=I=
MC+!TZH#^?U]]EI79K)&D+9_<-\D'[<K3^ WSM:"T_^"_^?_$W2E-YFI37?!P
MN1DT.VLR8Y(\ &8H3*@PS+(.!+B1?X^YWQ[ .=7J3<BP.IZXYF2,H96E(;BH
M-A1H4V4LU(@_17IVV]8H]EL^6AZ"LCX$N,/GV1Q#AWH>!1?XJ=/V?\90RBH1
MX.;^28%I@H<JB;H(+G+3ZUVW.SX:G+(V!+BI?]'"6BXA-$F2R8.!F$HJ7*BN
MRPC*2A#@CCU3L0B%%7)%/L,"UX+%E3RX2AT/+:V?XJX]U3P/#X<=MF\TH!^#
M%O1YN:S.7XU>+5E9 2ANU_\B>S0F [):0%RV%O"D5<?=>L;#3+OM%] %F0L;
M5VZ_&A$W0RAJ</()7Z](RC1Y8W'&R8]^TS62)(6I&FA+4.2R%E#<O.>:16[I
MS7;)0E4NO!H!UR9A)*7=4]R:B^#=;\,UDRM^MF^K$7H:S^[&OV%,I<_3BWS^
M/N%ZY:+T 12@UD&*4B8K3P(U@E9G:-Y*EZ>X21_)M@0R*(W(&Z%]-UZ)A:N=
MP_).#M;N3XK/S,7!D)@O0<=O=F&V>G_NW]]8E>9G[86R<'+/+]><P>YT#\#W
M2Z7L\<8=WXM_7T;_ %!+ P04    " #%@-52GZ ;\+$"  #B#   #0   'AL
M+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%D
MN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I
M#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#
M;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F?
M KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0
M&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH
M!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?
MA+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+
M"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TU
MMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%
M.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E
M=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$
M#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$#
M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #%@-52EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,6
MU5(<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y
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M%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04
M" #%@-52)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ Q8#54F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    " #%@-52!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,6 U5*L
MX;S:[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( ,6 U5*97)PC$ 8  )PG   3              "  <L!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Q8#54@J%Z,)S!
MB1$  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( ,6 U5*?H!OPL0(  .(,   -              "  ;4,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ Q8#54I>*NQS     $P(   L
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64$L%!@     )  D /@(  !44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d183984d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d183984d8k.htm">d183984d8k.htm</File>
    <File>d183984dex991.htm</File>
    <File>oric-20210616.xsd</File>
    <File>oric-20210616_lab.xml</File>
    <File>oric-20210616_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d183984d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d183984d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oric-20210616_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oric-20210616_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "oric-20210616.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "oric",
   "nsuri": "http://www.oricpharma.com/20210616",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d183984d8k.htm",
      "contextRef": "duration_2021-06-16_to_2021-06-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d183984d8k.htm",
      "contextRef": "duration_2021-06-16_to_2021-06-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oricpharma.com//20210616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-195039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-195039-xbrl.zip
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M6X/<<3<JF3=Z9#9^T654$(D"G:N(ZLT?DPR;[HQ8SQW? XYR>_0(.D@$%V9
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MR$A(1Q$>3;7_@(I=HN+;8#:@7B..Z<=AX\_ T7Y2.ZOD# Z+'K4>"?@.Q/3
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MN&2B?^@XS[VJ3D[B^^/N^ANYNKK#4,N\X E+K&>B:$RN)Y%3Z>)ZXB!CE_G
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M+A 7#\F5L-E$L0GW"RM'@Z/&*!GP @H3L& $G_ZSBO-S:=16T0@$&,T!^-B
M-& FAAX'D4Z5S^=HK#^<'AZRN!;66'> L.S5)]J\O_TZ^,SN6S?LLM^Z:??
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MP0R_;@IA/K[$) =%C<TIFI;S-4_+UOQ95)(/!?9G=T<#JS%.2L**\2,&+%=
M%454#?A0!%:=P<;YF5<$)6#[*5AR<@B6CYR3U)/-"8_]_EVC ]#3Y$\J><SZ
M'2029J KRU&LKE@G* (9PN(31(X/(L'9!),M/CP@48?,E%9[^]T=>#$4*>!^
MDOVR\W]M(]HS#N$." CFD$@B- B&82K9?Q.NXU-$_0H;@6W*'0?<RM>U'/*6
M(MV90'1%_HC( 6;#8&?Q=-G#>6H&9G",YH%4Z_@02=QX?\C"<9GR*H'PBDP&
M81I"/J%,$0\0*ZW'!'^.\0:"8#3M\ D<VR;.]&H4+B3&%.S7#QB#U@_QV^_"
M\_NO=PL0L.#&\8=?SAA8=0J!JI09/P5&[C4;Y^_@E>93M:?FJ'$))%4SDR,@
M6 BT+[)M.Z[B7U$9"$OZ@H@4&<$%G%'_2(15(S!13X:^FPB,' #ZY81[.MFV
M,5ZK[0X&D7RN6;V"P0;.I/X!A^/;(+G&<15>SM<X]P)1R4%W(L 9@2="&4/4
M )@YGLP#M \> _@?98'RYC F!D@ _, CAX0:4)PY(8%'U[1_56W?7Q[4%FF,
MU\V!-2\)_CACX:Q%#B57BU46HP35CQH%,Y$L<*L5K]PN6!,RPAC+FIAB$JR
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M==@[<*=Q"+B;L*<C-\SVX[K=/F5]([/=3NYVAAW?;K43AU[_ U!+ P04
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MYI7J_(SY,"\(ZY)_ %!+ 0(4 Q0    ( ,6 U5*^M./ZG!$  /%W   .
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H8RTR,#(Q,#8Q-E]P<F4N>&UL4$L%!@     %  4 0 $  %LY      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
